193 related articles for article (PubMed ID: 32811873)
1. STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population.
Canesin G; Maggio V; Palominos M; Stiehm A; Contreras HR; Castellón EA; Morote J; Paciucci R; Maitland NJ; Bjartell A; Hellsten R
Sci Rep; 2020 Aug; 10(1):13958. PubMed ID: 32811873
[TBL] [Abstract][Full Text] [Related]
2. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
[TBL] [Abstract][Full Text] [Related]
3. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.
Don-Doncow N; Escobar Z; Johansson M; Kjellström S; Garcia V; Munoz E; Sterner O; Bjartell A; Hellsten R
J Biol Chem; 2014 Jun; 289(23):15969-78. PubMed ID: 24755219
[TBL] [Abstract][Full Text] [Related]
4. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.
Civenni G; Longoni N; Costales P; Dallavalle C; García Inclán C; Albino D; Nuñez LE; Morís F; Carbone GM; Catapano CV
Mol Cancer Ther; 2016 May; 15(5):806-18. PubMed ID: 26826115
[TBL] [Abstract][Full Text] [Related]
5. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells.
Hellsten R; Johansson M; Dahlman A; Sterner O; Bjartell A
PLoS One; 2011; 6(7):e22118. PubMed ID: 21779382
[TBL] [Abstract][Full Text] [Related]
6. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
7. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
Hellsten R; Lilljebjörn L; Johansson M; Leandersson K; Bjartell A
Prostate; 2019 Oct; 79(14):1611-1621. PubMed ID: 31348843
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
10. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
Wang L; Lyu C; Stadlbauer B; Buchner A; Nößner E; Pohla H
Prostate; 2024 Feb; 84(2):131-147. PubMed ID: 37828768
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
Huang H; Wang C; Liu F; Li HZ; Peng G; Gao X; Dong KQ; Wang HR; Kong DP; Qu M; Dai LH; Wang KJ; Zhou Z; Yang J; Yang ZY; Cheng YQ; Tian QQ; Liu D; Xu CL; Xu DF; Cui XG; Sun YH
Clin Cancer Res; 2018 Sep; 24(18):4612-4626. PubMed ID: 29691294
[No Abstract] [Full Text] [Related]
13. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.
Handle F; Puhr M; Schaefer G; Lorito N; Hoefer J; Gruber M; Guggenberger F; Santer FR; Marques RB; van Weerden WM; Claessens F; Erb HHH; Culig Z
Mol Cancer Ther; 2018 Dec; 17(12):2722-2731. PubMed ID: 30254184
[TBL] [Abstract][Full Text] [Related]
14. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells.
García V; Lara-Chica M; Cantarero I; Sterner O; Calzado MA; Muñoz E
Oncotarget; 2016 Jan; 7(4):4490-506. PubMed ID: 26683224
[TBL] [Abstract][Full Text] [Related]
15. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
16. Investigation of ovatodiolide, a macrocyclic diterpenoid, as a potential inhibitor of oral cancer stem-like cells properties via the inhibition of the JAK2/STAT3/JARID1B signal circuit.
Lin CS; Bamodu OA; Kuo KT; Huang CM; Liu SC; Wang CH; Tzeng YM; Chao TY; Yeh CT
Phytomedicine; 2018 Jul; 46():93-103. PubMed ID: 30097127
[TBL] [Abstract][Full Text] [Related]
17. SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone.
Garrido-Rodríguez M; Ortea I; Calzado MA; Muñoz E; García V
J Proteomics; 2019 Feb; 193():217-229. PubMed ID: 30626528
[TBL] [Abstract][Full Text] [Related]
18. Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas.
Huang WC; Kuo KT; Adebayo BO; Wang CH; Chen YJ; Jin K; Tsai TH; Yeh CT
J Nutr Biochem; 2018 Apr; 54():140-150. PubMed ID: 29414668
[TBL] [Abstract][Full Text] [Related]
19. Esculentoside A suppresses breast cancer stem cell growth through stemness attenuation and apoptosis induction by blocking IL-6/STAT3 signaling pathway.
Liu C; Dong L; Sun Z; Wang L; Wang Q; Li H; Zhang J; Wang X
Phytother Res; 2018 Nov; 32(11):2299-2311. PubMed ID: 30080291
[TBL] [Abstract][Full Text] [Related]
20. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
